<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04608409</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-20-GYN-06</org_study_id>
    <nct_id>NCT04608409</nct_id>
  </id_info>
  <brief_title>Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer</brief_title>
  <official_title>A Phase I Dose-Escalation Study on the Safety of Lapatinib With Dose-Dense Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Frederick R. Ueland, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kentucky</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will be a phase I dose-escalation study of lapatinib and paclitaxel for&#xD;
      platinum-resistant ovarian cancer, which will establish the phase II dose for subsequent&#xD;
      efficacy trials.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      While ABCB1 (P-glycoprotein 1) upregulation after paclitaxel administration is well known,&#xD;
      there is currently no clinically available method for preventing or overcoming it. To develop&#xD;
      a therapy able to prevent ABCB1 upregulation and paclitaxel resistance, several ABCB1&#xD;
      inhibitors have been evaluated in combination with paclitaxel in preclinical model systems.&#xD;
      Pulsed-dose lapatinib and paclitaxel are synergistic and inhibition of ABCB1 by lapatinib&#xD;
      increases sensitivity to paclitaxel. Lapatinib is FDA approved, orally available, and&#xD;
      previously studied in combination with weekly paclitaxel for breast cancer at doses of 1000mg&#xD;
      to 1250mg daily (7000-8250mg per week). This trial will use twice-daily dosing of lapatinib&#xD;
      at a starting dose of 750 mg for 2 days (1500mg a day and 3000mg weekly dose), which is less&#xD;
      than half of the continuous dose and has been shown to achieve plasma concentrations at 48&#xD;
      hours that are associated with synergy. Therefore, these findings can be translated into a&#xD;
      novel, well-tolerated, and convenient combination regimen with significant potential for&#xD;
      clinical activity. This trial will be a phase I dose-escalation study of lapatinib and&#xD;
      paclitaxel for platinum-resistant ovarian cancer, which will establish the phase II dose for&#xD;
      subsequent efficacy trials.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 16, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2025</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival.</measure>
    <time_frame>One year</time_frame>
    <description>Proportion of patients with progression-free survival at one year.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-limiting toxicity</measure>
    <time_frame>4 weeks</time_frame>
    <description>Dose limiting toxicity (DLT) is calculated as the total number of patients experiencing DLTs divided by the total number treated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in plasma concentration of lapatinib.</measure>
    <time_frame>15 days (on day 1, 8 and 15)</time_frame>
    <description>Plasma concentrations of lapatinib will be measured on days 1, 8 and 15.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>ABCB1 Expression</measure>
    <time_frame>15 days (on day 1, 8 and 15)</time_frame>
    <description>Levels of ABCB1 expression (cell-free RNA) will be measured using Nanostring sequencing.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Lapatinib - Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group will receive Lapatinib (500mg PO BID) and Paclitaxel (80mg/m2).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lapatinib - Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group will receive Lapatinib (750mg PO BID) and Paclitaxel (80mg/m2).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lapatinib - Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group will receive Lapatinib (1500mg PO BID) and Paclitaxel (80mg/m2).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lapatinib - Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group will receive Lapatinib (2000mg PO BID) and Paclitaxel (80mg/m2).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lapatinib and Paclitaxel</intervention_name>
    <description>Participants will receive twice-daily Lapatinib, beginning two days prior to Paclitaxel treatment.</description>
    <arm_group_label>Lapatinib - Group 1</arm_group_label>
    <arm_group_label>Lapatinib - Group 2</arm_group_label>
    <arm_group_label>Lapatinib - Group 3</arm_group_label>
    <arm_group_label>Lapatinib - Group 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  histologically or cytologically confirmed ovarian cancer who recur within 12 months of&#xD;
             platinum-based chemotherapy&#xD;
&#xD;
          -  ECOG performance status less than or equal to 2&#xD;
&#xD;
          -  Adequate organ and marrow function at baseline&#xD;
&#xD;
          -  ability to sign a written informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  hypersensitivity to lapatinib or paclitaxel&#xD;
&#xD;
          -  uncontrolled intercurrent illness&#xD;
&#xD;
          -  receiving medications that inhibit or induce CYP3A4&#xD;
&#xD;
          -  malabsorption syndrome&#xD;
&#xD;
          -  congestive heart failure&#xD;
&#xD;
          -  receiving any other anti-cancer investigational agents&#xD;
&#xD;
          -  baseline neuropathy greater than Grade 1&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frederick Ueland, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Markey Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frederick Ueland, MD</last_name>
    <phone>859-257-4550</phone>
    <email>fuela0@uky.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Markey Cancer Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>October 22, 2020</study_first_submitted>
  <study_first_submitted_qc>October 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2020</study_first_posted>
  <last_update_submitted>December 7, 2020</last_update_submitted>
  <last_update_submitted_qc>December 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kentucky</investigator_affiliation>
    <investigator_full_name>Frederick R. Ueland, M.D.</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>platinum-resistant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Lapatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

